Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the same with $100.00. Discover outperforming stocks and ...

DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this ...

Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong ...

Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness ...

Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose monitoring receivers have been recalled due to speaker malfunctions, which ...

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...

The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version. In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some ...

On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of ...